These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22963555)

  • 21. When is good good enough for HIV-1 prophylaxis?
    Buchbinder S
    Lancet Infect Dis; 2014 Nov; 14(11):1024-1025. PubMed ID: 25300861
    [No Abstract]   [Full Text] [Related]  

  • 22. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco.
    Liu A; Cohen S; Follansbee S; Cohan D; Weber S; Sachdev D; Buchbinder S
    PLoS Med; 2014 Mar; 11(3):e1001613. PubMed ID: 24595035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
    Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
    Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virological efficacy of abacavir: systematic review and meta-analysis.
    Cruciani M; Mengoli C; Malena M; Serpelloni G; Parisi SG; Moyle G; Bosco O
    J Antimicrob Chemother; 2014 Dec; 69(12):3169-80. PubMed ID: 25074854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
    Raffi F; Rachlis A; Brinson C; Arasteh K; Górgolas M; Brennan C; Pappa K; Almond S; Granier C; Nichols WG; Cuffe RL; Eron J; Walmsley S
    AIDS; 2015 Jan; 29(2):167-74. PubMed ID: 25387312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
    Nishijima T; Komatsu H; Teruya K; Tanuma J; Tsukada K; Gatanaga H; Kikuchi Y; Oka S
    AIDS; 2013 Mar; 27(5):839-42. PubMed ID: 23719354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
    Khanlou H; Farthing C
    AIDS Patient Care STDS; 2006 Sep; 20(9):604-5. PubMed ID: 16987045
    [No Abstract]   [Full Text] [Related]  

  • 28. CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral load.
    Condoluci DV; Andrews M; Luber AD
    AIDS Read; 2008 Aug; 18(8):410-2. PubMed ID: 18770899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.
    d'Ettorre G; Zaffiri L; Ceccarelli G; Andreotti M; Massetti AP; Vella S; Mastroianni CM; Vullo V
    HIV Clin Trials; 2007; 8(3):182-8. PubMed ID: 17621465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fanconi syndrome-like tubular acidosis associated with a tenofovir-containing antiretroviral regimen in a human immunodeficiency virus-1-infected Asian woman.
    Kiyasu Y; Koganemaru H; Hitomi S
    J Infect Chemother; 2012 Apr; 18(2):255-7. PubMed ID: 21918819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-HIV agents. Low rate of early virologic failure seen with a combination of Trizivir and tenofovir.
    TreatmentUpdate; 2004 Mar; 16(2):2-3. PubMed ID: 17219666
    [No Abstract]   [Full Text] [Related]  

  • 32. Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.
    Ferrer E; Gatell JM; Sanchez P; Domingo P; Puig T; Niubo J; Cortes C; Veloso S; Pedrol E; Leon A; Gutierrez M; Podzamczer D
    AIDS Res Hum Retroviruses; 2008 Jul; 24(7):931-4. PubMed ID: 18671476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Bayonne Kombo ES; Gathse A
    Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
    [No Abstract]   [Full Text] [Related]  

  • 34. Integrating HIV prevention into practice.
    Mathers BM; Cooper DA
    JAMA; 2014 Jul 23-30; 312(4):349-50. PubMed ID: 25038352
    [No Abstract]   [Full Text] [Related]  

  • 35. Complera for the treatment of HIV.
    Belavic JM
    Nurse Pract; 2013 Jul; 38(7):8-10. PubMed ID: 23778174
    [No Abstract]   [Full Text] [Related]  

  • 36. HPV oral infection. Case report of an HIV-positive Nigerian sex worker.
    Martini S; Colella G; Masiello A; Lanza A; Pisapia R; Cascone A; Di Martino F; Filippini A; Filippini P
    Infez Med; 2007 Jun; 15(2):115-8. PubMed ID: 17598999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
    Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
    Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preexposure chemoprophylaxis for HIV prevention.
    Pimpinella G; Malgarini RB
    N Engl J Med; 2011 Apr; 364(14):1373; author reply 1374-5. PubMed ID: 21470024
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction.
    Francisci D; Falcinelli E; Belfiori B; Petito E; Fierro T; Baldelli F; Gresele P
    AIDS Patient Care STDS; 2011 Oct; 25(10):567-9. PubMed ID: 21851265
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
    Anderson PL; Kiser JJ; Gardner EM; Rower JE; Meditz A; Grant RM
    J Antimicrob Chemother; 2011 Feb; 66(2):240-50. PubMed ID: 21118913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.